Guardant Health develops breakthrough diagnostic technologies to improve cancer management. With Guardant360, we offer real-time, biopsy-free tumor sequencing that tracks tumor genomics in real-time and identifies associated treatment options. The recent introduction of groundbreaking analytical tools, including our Tumor Response Map and a mobile-enabled physician portal, further advance Guardant Health's momentum.
Guardant Health has raised almost $200M from OrbiMed, Sequoia Capital, Khosla Ventures, Lightspeed Venture Partners, and Formation8, and is led by a seasoned management team of thought leaders and successful serial entrepreneurs in next generation sequencing and rare cell diagnostics. They are advised by an oncologist-led medical steering committee from leading cancer centers.